N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)

Top Cited Papers
Publisher Website
Google Scholar
Abstract
No abstract available
Funding Information
  • Bristol-Myers Squibb, Co.
  • Pfizer Inc.
  • Bristol-Myers Squibb Co.
  • Boehringer-Ingelheim
  • AstraZeneca, Merck/Schering-Plough, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline
  • AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Schering-Plough
  • Boehringer-Ingelheim, AstraZeneca, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and Schering-Plough/Merck
  • AstraZeneca and Boehringer-Ingelheim
  • Bristol-Myers Squibb/Pfizer
  • Alere, AstraZeneca, Amgen, Abbott, Servier, Johnson & Johnson, Pfizer, and Bristol-Myers Squibb
  • sanofi-aventis, St. Jude Medical, Boehringer-Ingelheim, Cardiome, Pfizer, Bayer, and Bristol-Myers Squibb
  • sanofi-aventis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, Medtronic, and St. Jude Medical
  • Bristol-Myers Squibb and Pfizer
  • AstraZeneca, Bristol-Myers Squibb/Pfizer, Boehringer-Ingelheim, Bayer, Daiichi Sankyo, and sanofi-aventis
  • Johnson & Johnson, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, and Ortho-McNeil-Janssen
  • Boehringer Ingelheim and Bayer
  • Bristol-Myers Squibb, AstraZeneca, Boehringer-Ingelheim, and Daiichi Sankyo
  • Bristol-Myers Squibb and Boehringer-Ingelheim
  • Bristol-Myers Squibb, Boehringer-Ingelheim, Astellas, AstraZeneca, GlaxoSmithKline, Medtronic Foundation, Merck, sanofi-aventis, and the Medicines Company
  • Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, AstraZeneca, Eli Lily, GlaxoSmithKline, Hoffman-La Roche, Novartis, Otsuka, Sanofi-Aventis, and the Medicines Company
  • Pfizer, Novartis, Otsuka, and Hoffmann-La Roche